← Eichor
Study identifier: NCT06952517 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

Condition: Papular-pustular Rosacea · Papulopustular Rosacea (PPR) · Papulopustular Rosacea  ·  Sponsor: Narrows Institute for Biomedical Research

PhasePhase 2
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.

This description comes directly from the study's public registry record.

Talk to the study team

Kayla N Zafar, BA  ·  718-836-6600  ·  kayla.zafar@va.gov

Always discuss trial participation with your own doctor first.

Locations (1)

New York Harbor VA Brooklyn CampusBrooklyn, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06952517